Only about 7% of cancer patients benefit from targeted therapies¹, often because treatment isn’t correctly matched to the genetic changes causing the tumor to grow.
We combine advanced proprietary AI with a multidisciplinary expert review to evaluate your cancer as a complete biological system.
Only about 7% of cancer patients benefit from targeted therapies¹, often because treatment isn’t correctly matched to the genetic changes causing the tumor to grow.
You trust your care team. But cancer is complex and constantly evolving. New therapies, biomarkers, and scientific evidence emerge faster than any one physician can fully evaluate for every patient.
That leaves one uncomfortable question: What if there’s something important we’re not seeing?
At the core of our service is Genomate®, our computational reasoning technology (an advanced form of AI) developed over the last 10 years and used on thousands of patients, applying the same logic as an oncologist would with unlimited time per patient. It systematically analyzes your full genomic profile, biomarkers, and clinical context. Unlike tools that analyze individual mutations or generate generic summaries based on patterns, Genomate evaluates how alterations interact, how pathways influence one another, and how current scientific evidence applies to your specific tumor.
Every result is then reviewed by a multidisciplinary team, ensuring your report is comprehensive, clinically grounded, and actionable.
Computational reasoning + multidisciplinary review (genomic experts trained in molecular-based treatments and board-certified oncologists)
Manual review of fragmented data
Your cancer is evaluated as a complete biological system, not just individual mutations
Your genomic results are reviewed in a full clinical context
Treatment may be based on partial or fragmented information
Important genomic insights may not be fully considered
Identifies how genetic alterations interact, including resistance and treatment response
Uncovers patterns that may impact what actually works
Limited understanding of how findings interact
Critical drivers of treatment response may be overlooked
Confirms whether your current treatment is the right choice
Identifies additional options, including clinical trials
Decisions rely on the initial evaluation alone
Potential treatment options may never be explored
Clear, structured report with actionable insights
Designed to support real conversations with your oncologist
Information may be fragmented or difficult to interpret
Uncertainty about what actually matters
Confidence that all relevant factors were evaluated
Greater clarity before making your next move
You may move forward without fully exploring all options (and can’t go back later)
Risk of undergoing treatments that may not be effective for your tumor
That complete view allows physicians to assess what treatment paths are reasonable to consider, which options are well supported by evidence, and where uncertainty remains.
For some people, this confirms that their current plan is the right one.
For others, it highlights additional options to discuss.
Either way, the goal is the same: to help you and your loved ones move forward with confidence, not unanswered “what ifs.”
Grounded in over 20 years of research, Genomate is part of a new generation of oncology innovation, recognized by organizations such as ASCO, Mayo Clinic, and CancerX. Built to medical-grade standards (ISO 13485) and independently certified for data security (ISO 27001 by BSI), with cross-border protection under the EU–U.S. Data Privacy Framework.
.avif){kind=logo}
.avif){kind=logo}
You or a loved one can upload the medical records and results you have from your provider (examples of commonly used NGS tests: Foundation Medicine, Caris Life Sciences, Tempus, Guardant Health, Illumina, and others).
Genomate analyzes your cancer as a connected biological system rather than isolated mutations. It evaluates pathways, resistance patterns, and scientific evidence at scale.
Backed by peer-reviewed research published in leading journals such as Nature Precision Oncology, Journal of Clinical Oncology, and World Journal of Pediatrics, among others. View our publications here.
Our team of molecular genetics experts, together with a licensed oncologist review the full analysis, apply clinical judgment, and determine what is possible and feasible for your next steps. Based on those insights, the oncologist begins preparing your second opinion report.
You, or you and a loved one will meet directly with the oncologist via telehealth. They’ll explain what was considered, what stands out, and why certain treatment paths may or may not make sense for your cancer.
You’ll receive a written report you can revisit or share with your care team. The report includes a clear summary of the treatment options reviewed, the physician’s clinical reasoning, areas of uncertainty or conflicting evidence, and references to relevant scientific literature.
"When I got my treatment plan, I couldn’t shake the ‘what if we’re missing something’ feeling. The Genomate Second Opinion helped me understand my cancer in a way I hadn’t before. I finally feel confident moving ahead without second-guessing everything."
"My daughter insisted I try it, but I was worried it would mean more testing and delays. In reality, they used the results I already had, and the process was much faster than I expected. I was able to explore additional treatment options without interrupting my care.”
“The second time, I couldn’t afford to miss anything, and traveling to a specialized cancer center wasn’t an option for me. Genomate gave me access to that level of insight without leaving home, and helped me understand what I was dealing with.”
One decision can shape your long-term outcome. Make sure it’s the right one.
$1,495
HSA/FSA eligible*
Review of current treatment plan
Evaluation of genomic findings and biomarkers
Identification of additional treatment considerations
Relevant clinical trial pathways (if applicable)
Clear explanation in patient-friendly language
Written report you can review with your oncologist
1. Marquart J, Chen EY, Prasad V. Estimation of the Percentage of US Patients With Cancer Who Benefit From Genome-Driven Oncology. JAMA Oncol. 2018;4(8):1093-1098. doi:10.1001/jamaoncol.2018.1660
This service provides an expert second opinion from a qualified medical professional based on the molecular test results submitted by the patient. It does not replace, supersede, or substitute the care provided by the patient’s treating physician. Rather, it is intended to support shared clinical decision-making by providing a second opinion from a qualified medical professional.
.avif)
